Clinical development of listeria monocytogenes–based immunotherapies
DT Le, TW Dubensky Jr, DG Brockstedt - Seminars in oncology, 2012 - Elsevier
Active immunotherapy targeting dendritic cells (DCs) has shown great promise in preclinical
models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T
(Provenge, Dendreon, Seattle, WA), which consists of antigen-loaded dendritic cells (DCs),
recently became the first targeted therapeutic cancer vaccine to be approved by the US
Food and Drug Administration (FDA). However, ex vivo therapies such as Provenge have
practical limitations and elicit an immune response with limited scope. By contrast, live …
models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T
(Provenge, Dendreon, Seattle, WA), which consists of antigen-loaded dendritic cells (DCs),
recently became the first targeted therapeutic cancer vaccine to be approved by the US
Food and Drug Administration (FDA). However, ex vivo therapies such as Provenge have
practical limitations and elicit an immune response with limited scope. By contrast, live …